Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), informed the Company that he would be retiring due to health and family-related considerations. On April 9, 2014, Mr. Aasen informed the Company that his last day will be April 18, 2014. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares after opening at $17.87 moved to $18.36 on last trade day and at the end of the day closed at $18.36. Company price to sales ratio in past twelve months was calculated as 1643.39 and price to cash ratio as 9.73. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) showed a negative weekly performance of -12.53%.
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Wednesday, StockRatingsNetwork.com reports. The firm currently has a $2.10 target price on the stock. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -8.00% in last trading session and ended the day on $1.84. FOLD return on equity ratio is recorded as -144.30% and its return on assets is -64.10%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) yearly performance is -36.55%.
Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, on 8 April announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation. Ambit Biosciences Corp (NASDAQ:AMBI) shares moved down -6.29% in last trading session and was closed at $6.26, while trading in range of $5.75 – $6.58. Ambit Biosciences Corp (NASDAQ:AMBI) year to date (YTD) performance is -35.06%.
Incyte (NASDAQ:INCY)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued on Thursday, Analyst Ratings.Net reports. They currently have a $55.00 target price on the stock. Zacks‘s price target would indicate a potential upside of 18.92% from the stock’s previous close. Incyte Corporation (NASDAQ:INCY) weekly performance is -12.13%. On last trading day company shares ended up $43.10. Incyte Corporation (NASDAQ:INCY) distance from 50-day simple moving average (SMA50) is -28.48%. Analysts mean target price for the company is $72.15.